Matches in SemOpenAlex for { <https://semopenalex.org/work/W2515795531> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2515795531 endingPage "281" @default.
- W2515795531 startingPage "281" @default.
- W2515795531 abstract "281 Background: A combination of capecitabine (CAP) and temozolomide (TEM) has been successfully used as first-line treatment in low-grade pancreatic neuroendocrine neoplasms (PNEN). We reviewed activity and toxicity of the same regimen in patients with advanced NEN with different primary and grading. Methods: Clinical data of patients who had received oral CAP 1500 mg/m2/day over 14 days bid plus oral TEM 150-200 mg/m2/day on days 10-14 of each 28-day cycle, were retrospectively reviewed. The methylenguanilmetiltransferase (MGMT) methylation-status (MGMT-gene >5% = responders) and TS-polymorphisms (2R/2R, 2R/3R = responders, 3R/3R = non-responders) in tumor-tissue/peripheral-blood were evaluated by pyrosequencing. Results: Since March 2012, 29 patients were selected. The primary tumor was: pancreas in 14 patients (48%), gastrointestinal (GI) in 5 (17%), unknown in 2 (7%), lung in 8 (28%). According to 2010 WHO classification, Ki67 was <2% (G1) in 3%, 3-20% (G2) in 45% patients, >20% (G3) in 21% with two low G3 (Ki67 21-30%), and unknown in 3%. Among lung: 7% typical and 21% atypical (Travis’ classification). 72% patients (21/29) were progressive on different therapies: peptide-receptor-radiotherapy (38%), chemotherapy (38%), everolimus (14%). Partial-response (PR) occurred in 14% (4/29) of patients (95% CI: 4-32), stable-disease (SD) in 59% (17/29) (95% CI: 39-77) mainly PNET. The two low G3 responded. Disease control rate (PR+SD): 72% (95% CI: 53-87). Median TTP: 9 months (95% CI: 5.6-N.E.). Thrombocytopenia was the most frequent grade 3 toxicity, always temporary. All 4 PR patients had genotype 2R/3R-2R/2R investigated for the 28 base-pair (bp) variable number of tandem repeats (VNTR) in the 5'UTR of the TS-gene, and MGMT-gene inactivation by epigenetic silencing. Conclusions: This analysis suggests that CAP-TEM chemotherapy could be active and well tolerated in pretreated patients with advanced NEN of different origins and grading. This warrants a prospective investigation in a more homogeneous population (G2 and “low-G3” GEP NEN or lung carcinoids), in order to validate the predictive value of MGMT methylation-status and TS-polymorphisms." @default.
- W2515795531 created "2016-09-16" @default.
- W2515795531 creator A5002745641 @default.
- W2515795531 creator A5020435379 @default.
- W2515795531 creator A5021501173 @default.
- W2515795531 creator A5022190084 @default.
- W2515795531 creator A5023215623 @default.
- W2515795531 creator A5024763432 @default.
- W2515795531 creator A5066059020 @default.
- W2515795531 creator A5071532685 @default.
- W2515795531 creator A5075099899 @default.
- W2515795531 creator A5078823780 @default.
- W2515795531 creator A5083367244 @default.
- W2515795531 creator A5085512648 @default.
- W2515795531 date "2014-01-20" @default.
- W2515795531 modified "2023-10-18" @default.
- W2515795531 title "Capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NEN): An Italian multicenter retrospective analysis." @default.
- W2515795531 doi "https://doi.org/10.1200/jco.2014.32.3_suppl.281" @default.
- W2515795531 hasPublicationYear "2014" @default.
- W2515795531 type Work @default.
- W2515795531 sameAs 2515795531 @default.
- W2515795531 citedByCount "10" @default.
- W2515795531 countsByYear W25157955312014 @default.
- W2515795531 countsByYear W25157955312015 @default.
- W2515795531 countsByYear W25157955312017 @default.
- W2515795531 countsByYear W25157955312018 @default.
- W2515795531 countsByYear W25157955312019 @default.
- W2515795531 countsByYear W25157955312023 @default.
- W2515795531 crossrefType "journal-article" @default.
- W2515795531 hasAuthorship W2515795531A5002745641 @default.
- W2515795531 hasAuthorship W2515795531A5020435379 @default.
- W2515795531 hasAuthorship W2515795531A5021501173 @default.
- W2515795531 hasAuthorship W2515795531A5022190084 @default.
- W2515795531 hasAuthorship W2515795531A5023215623 @default.
- W2515795531 hasAuthorship W2515795531A5024763432 @default.
- W2515795531 hasAuthorship W2515795531A5066059020 @default.
- W2515795531 hasAuthorship W2515795531A5071532685 @default.
- W2515795531 hasAuthorship W2515795531A5075099899 @default.
- W2515795531 hasAuthorship W2515795531A5078823780 @default.
- W2515795531 hasAuthorship W2515795531A5083367244 @default.
- W2515795531 hasAuthorship W2515795531A5085512648 @default.
- W2515795531 hasConcept C121608353 @default.
- W2515795531 hasConcept C126322002 @default.
- W2515795531 hasConcept C143998085 @default.
- W2515795531 hasConcept C2776694085 @default.
- W2515795531 hasConcept C2777389519 @default.
- W2515795531 hasConcept C2777909004 @default.
- W2515795531 hasConcept C2778822529 @default.
- W2515795531 hasConcept C2779066768 @default.
- W2515795531 hasConcept C2779699572 @default.
- W2515795531 hasConcept C2781413609 @default.
- W2515795531 hasConcept C509974204 @default.
- W2515795531 hasConcept C526805850 @default.
- W2515795531 hasConcept C71924100 @default.
- W2515795531 hasConcept C90924648 @default.
- W2515795531 hasConceptScore W2515795531C121608353 @default.
- W2515795531 hasConceptScore W2515795531C126322002 @default.
- W2515795531 hasConceptScore W2515795531C143998085 @default.
- W2515795531 hasConceptScore W2515795531C2776694085 @default.
- W2515795531 hasConceptScore W2515795531C2777389519 @default.
- W2515795531 hasConceptScore W2515795531C2777909004 @default.
- W2515795531 hasConceptScore W2515795531C2778822529 @default.
- W2515795531 hasConceptScore W2515795531C2779066768 @default.
- W2515795531 hasConceptScore W2515795531C2779699572 @default.
- W2515795531 hasConceptScore W2515795531C2781413609 @default.
- W2515795531 hasConceptScore W2515795531C509974204 @default.
- W2515795531 hasConceptScore W2515795531C526805850 @default.
- W2515795531 hasConceptScore W2515795531C71924100 @default.
- W2515795531 hasConceptScore W2515795531C90924648 @default.
- W2515795531 hasIssue "3_suppl" @default.
- W2515795531 hasLocation W25157955311 @default.
- W2515795531 hasOpenAccess W2515795531 @default.
- W2515795531 hasPrimaryLocation W25157955311 @default.
- W2515795531 hasRelatedWork W2011916383 @default.
- W2515795531 hasRelatedWork W2148829499 @default.
- W2515795531 hasRelatedWork W2152154338 @default.
- W2515795531 hasRelatedWork W2247624284 @default.
- W2515795531 hasRelatedWork W2512663019 @default.
- W2515795531 hasRelatedWork W2747212876 @default.
- W2515795531 hasRelatedWork W2754131662 @default.
- W2515795531 hasRelatedWork W2766512167 @default.
- W2515795531 hasRelatedWork W3031320675 @default.
- W2515795531 hasRelatedWork W3113691267 @default.
- W2515795531 hasVolume "32" @default.
- W2515795531 isParatext "false" @default.
- W2515795531 isRetracted "false" @default.
- W2515795531 magId "2515795531" @default.
- W2515795531 workType "article" @default.